<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190255</url>
  </required_header>
  <id_info>
    <org_study_id>P030412</org_study_id>
    <nct_id>NCT00190255</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics of Gastrointestinal Bleeding</brief_title>
  <official_title>Pharmacogenetics of Gastrointestinal Bleeding Under Nonsteroidal Anti-inflammatory Drugs : the Role of Cytochrome P450 2C9</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastrointestinal bleeding is a severe adverse effect occurring in subjects secondary to the
      use of nonsteroidal anti-inflammatory drugs (NSAIDs). The enzyme CYP2C9 is responsible for
      the elimination of several NSAIDs. This protein is inactive in 12% of the subjects because of
      genetic mutations. We hypothesized that individuals carrying such mutations should be at
      higher risk of gastrointestinal bleeding since they display decreased NSAIDs elimination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastrointestinal bleeding is a severe adverse effect occurring in subjects secondary to the
      use of nonsteroidal anti-inflammatory drugs (NSAIDs). The enzyme CYP2C9 is responsible for
      the elimination of most NSAIDs. Several polymorphisms have been observed in CYP2C9. Of these,
      the CYP2C9*3 allele, found in 12% of caucasian subjects, leads to reduced function of the
      enzyme.

      We hypothesized that individuals carrying this mutation should be at higher risk of
      gastrointestinal bleeding since they display decreased elimination of some NSAIDs.

      The purpose of this study is to determine whether the frequency for CYP2C9*3 variant allele
      is increased in subjects using NSAIDs metabolized by CYP2C9 in comparison with subjects under
      NSAIDs not metabolized by this enzyme.

      The study groups consist of 200 patients suffering from gastrointestinal bleeding after
      NSAIDs use, divided in 100 patients using NSAIDs metabolized by CYP2C9 and 100 patients using
      other NSAIDs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">200</enrollment>
  <condition>Gastrointestinal Hemorrhage</condition>
  <condition>Stomach Ulcer</condition>
  <condition>Non-steroidal Anti-inflammatory Drug Sensitivity</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CY2PC9 genotyping</intervention_name>
    <description>CY2PC9 genotyping</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Gastrointestinal bleeding is a severe adverse effect occurring in subjects secondary to the
      use of nonsteroidal anti-inflammatory drugs (NSAIDs). The enzyme CYP2C9 is responsible for
      the elimination of several NSAIDs. This protein is inactive in 12% of the subjects because of
      genetic mutations. We hypothesized that individuals carrying such mutations should be at
      higher risk of gastrointestinal bleeding since they display decreased NSAIDs elimination.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion Criteria:

          -  Upper gastrointestinal bleeding revealed by hematemesis, melena or lowering of at
             least 2g/dl of haemoglobin

          -  Endoscopic report of gastrointestinal ulcer or haemorrhagic lesion

          -  Immediate antecedents of NSAID therapy

        Exclusion Criteria:

          -  Cirrhosis (Child B or C)

          -  Coma

          -  Concomitant therapy with substrates or inhibitors of CYP2C9 : ketoconazole,
             itraconazole, ritonavir, phenobarbital, rifampicin, depakine, phenytoin, St John's
             worts

          -  Patients treated by a NSAID metabolized by CYP2C9 and a NSAID not metabolized by
             CYP2C9
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Upper gastrointestinal bleeding revealed by hematemesis, melena or lowering of at
             least 2g/dl of haemoglobin

          -  Endoscopic report of gastrointestinal ulcer or haemorrhagic lesion

          -  Immediate antecedents of NSAID therapy

        Exclusion Criteria:

          -  Cirrhosis (Child B or C)

          -  Coma

          -  Concomitant therapy with substrates or inhibitors of CYP2C9 : ketoconazole,
             itraconazole, ritonavir, phenobarbital, rifampicin, depakine, phenytoin, St John's
             worts

          -  Patients treated by a NSAID metabolized by CYP2C9 and a NSAID not metabolized by
             CYP2C9
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas CARBONNELL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent BECQUEMONT, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'hépato-gastroentérologie, Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'hépato-gastroentérologie, Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>: Service d'hépato-gastroentérologie, Hôpital Henri Mondor</name>
      <address>
        <city>Paris</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'hépato-gastroentérologie, Hôpital Paul BROUSSE</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br J Clin Pharmacol. 2001 Jun;51(6):627-30.</citation>
    <PMID>11422024</PMID>
  </reference>
  <reference>
    <citation>Martínez C, Blanco G, Ladero JM, García-Martín E, Taxonera C, Gamito FG, Diaz-Rubio M, Agúndez JA. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol. 2004 Jan;141(2):205-8. Epub 2004 Jan 5.</citation>
    <PMID>14707031</PMID>
  </reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>May 9, 2011</last_update_submitted>
  <last_update_submitted_qc>May 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Christophe AUCAN</name_title>
    <organization>Department Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>gastrointestinal haemorrhage</keyword>
  <keyword>stomach ulcer</keyword>
  <keyword>anti-inflammatory agents, non-steroidal</keyword>
  <keyword>CYP2C9 protein, human</keyword>
  <keyword>genotype</keyword>
  <keyword>pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

